KANGHUI PHARMACEUTICAL(603139)

Search documents
康惠制药:上半年亏损4020.36万元
Zheng Quan Shi Bao Wang· 2025-08-26 07:55
人民财讯8月26日电,康惠制药(603139)8月26日晚间披露2025年半年报,上半年实现营业收入2.48亿 元,同比下降6.83%;归母净利润-4020.36万元;基本每股收益-0.4元。本期业绩亏损主要原因为:(1)控 股子公司陕西友帮固定资产折旧及融资贷款利息费用较大,同时,产品市场供需关系变动大,产品收益 不及预期,导致陕西友帮2025年上半年仍亏损较大;(2)控股子公司春盛药业受市场环境影响,业务下 滑明显,致亏损较大;(3)母公司成本费用增加。 ...
康惠制药:上半年归母净利润亏损4020.36万元,同比亏损扩大
Xin Lang Cai Jing· 2025-08-26 07:55
Group 1 - The company reported a revenue of 248 million yuan for the first half of the year, representing a year-on-year decrease of 6.83% [1] - The net profit attributable to shareholders was a loss of 40.2 million yuan, compared to a loss of 8.7 million yuan in the same period last year [1] - The basic earnings per share were -0.4 yuan [1]
康惠制药(603139.SH)发布上半年业绩,归母净亏损4020.36万元,扩大362.01%
智通财经网· 2025-08-26 07:54
智通财经APP讯,康惠制药(603139.SH)发布2025年半年度报告,该公司营业收入为2.48亿元,同比减少 6.83%。归属于上市公司股东的净亏损为4020.36万元,同比扩大362.01%。归属于上市公司股东的扣除 非经常性损益的净亏损为4282.71万元,同比扩大167.89%。基本每股亏损为0.4元。 ...
康惠制药: 康惠制药关于换发药品生产许可证的公告
Zheng Quan Zhi Xing· 2025-08-25 16:31
Core Points - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., has obtained a new drug production license valid until August 24, 2030, ensuring compliance and continuity in operations [1][2] - The new license was issued by the Shaanxi Provincial Drug Administration due to the expiration of the previous license, which is a routine regulatory process [1][2] Company Information - The new drug production license number is 陕 20160073, and the company is located in Xi'an, Shaanxi Province [1] - The legal representative and responsible person for quality is Wang Yanling, while the production manager is Guo Jiangang [1] Production Scope - The company is authorized to produce a variety of pharmaceutical forms including plasters, ointments, granules, hard capsules, tablets, tinctures, and more across multiple production sites in Xi'an [1]
康惠制药:关于换发药品生产许可证的公告
Zheng Quan Ri Bao· 2025-08-25 13:44
证券日报网讯 8月25日晚间,康惠制药发布公告称,公司于2025年8月25日取得陕西省药品监督管理局 换发的《药品生产许可证》。 (文章来源:证券日报) ...
康惠制药:公司为控股子公司提供担保余额约为1.12亿元
Mei Ri Jing Ji Xin Wen· 2025-08-25 08:48
Group 1 - The core point of the article is that Kanghui Pharmaceutical has provided guarantees totaling approximately 112 million yuan for its subsidiaries, which represents 13.35% of the company's latest audited net assets [1] - As of the announcement date, the market capitalization of Kanghui Pharmaceutical is 2.4 billion yuan [1] - The revenue composition for Kanghui Pharmaceutical in 2024 is as follows: 49.58% from pharmaceutical manufacturing, 47.35% from pharmaceutical distribution, and 3.07% from other businesses [1] Group 2 - The company has provided a guarantee balance of 2.8 million yuan for its wholly-owned subsidiary [1] - The A-share market has seen a continuous trading volume exceeding 2 trillion yuan for eight consecutive days, indicating a robust trading environment [1] - Major industry players are actively recruiting for 25 positions, highlighting a demand for talent in the sector [1]
康惠制药(603139) - 康惠制药关于为控股子公司提供担保的公告
2025-08-25 08:15
关于为控股子公司提供担保的公告 证券代码:603139 证券简称:康惠制药 公告编号:2025-051 陕西康惠制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: | | | 被担保人名称 本次担保金额 | 480 | 四川春盛药业集团股份有限公司 万元 | | | --- | --- | --- | --- | --- | --- | | 担 | 保 对 | | | | | | 象 | | 实际为其提供的担保余额 | 2,880 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用:_________ | | | | 本次担保是否有反担保 | 是 | □否 | □不适用:_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额(万元) | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额(万元) | 11,442.84 | | 对外担保总额占上市公司最近一期经审计净资产的比例(%) | 13.35 ...
康惠制药(603139) - 康惠制药关于换发药品生产许可证的公告
2025-08-25 08:15
证券代码:603139 证券简称:康惠制药 公告编号:2025-052 陕西康惠制药股份有限公司 关于换发药品生产许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 一、《药品生产许可证》的主要信息 企业名称:陕西康惠制药股份有限公司 许可证编号:陕 20160073 社会信用代码:916100006984144239 分类码:AhzCz 注册地址:陕西省咸阳市秦都区高新技术产业开发区彩虹二路 法定代表人:王延岭 企业负责人:王延岭 质量负责人:郝红梅 质量授权人:郝红梅 陕西康惠制药股份有限公司(以下简称"公司")于 2025 年 8 月 25 日取得 陕西省药品监督管理局换发的《药品生产许可证》(许可证编号:陕 20160073), 换发后的《药品生产许可证》有效期至 2030 年 8 月 24 日,具体情况如下: 生产地址和生产范围: 陕西省咸阳市秦都区高新技术产业开发区胭脂路 36 号:膏药,软膏剂,茶 剂,颗粒剂,硬胶囊剂,片剂,酒剂,合剂,搽剂,酊剂,洗剂; 陕西省咸阳市秦都区高新开发区高新路:搽剂,酊剂 ...
陕西康惠制药股份有限公司 第五届董事会第十八次会议决议公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-08-20 19:48
Group 1 - The company held its 18th meeting of the 5th Board of Directors on August 19, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][5] - The board approved the proposal to cancel the supervisory board and amend the Articles of Association, transferring the supervisory board's powers to the audit committee of the board [3][39] - The proposal to amend the Articles of Association requires approval at the company's second extraordinary general meeting in 2025 [4] Group 2 - The board also approved the revision of 23 governance rules to enhance the company's governance structure, which will also be submitted for approval at the upcoming extraordinary general meeting [6][39] - A new management system for the departure of directors and senior management was established and disclosed [7] - The board nominated candidates for the 6th Board of Directors, including both non-independent and independent directors, all requiring approval at the extraordinary general meeting [9][15][39] Group 3 - The company announced the date and details for the second extraordinary general meeting, scheduled for September 4, 2025, at 14:30 [21][20] - Voting will be conducted through a combination of on-site and online methods, with specific timeframes for each [22][24] - The company will provide reminders to minority investors to ensure their participation in the voting process [27]
陕西康惠制药股份有限公司 关于董事会换届选举的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-08-20 19:48
Core Viewpoint - The company is undergoing a board restructuring process, including the nomination of candidates for the sixth board of directors and the establishment of new governance policies to enhance operational standards and corporate governance [3][4][20]. Group 1: Board Restructuring - The fifth board of directors has completed its term, and the company plans to elect a new sixth board consisting of nine members, including three independent directors and one employee representative [3][5]. - The board candidates have been nominated and will be subject to approval at the upcoming extraordinary general meeting [4][5]. - The election will utilize a cumulative voting system, and the new board's term will commence upon approval by the shareholders [5]. Group 2: Governance Policy Updates - The company is revising several governance policies, including the management of resignations for directors and senior management, to align with legal requirements and improve governance structures [2]. - The revised policies will also be presented for approval at the extraordinary general meeting [2]. Group 3: Candidate Qualifications - All nominated candidates meet the legal and regulatory requirements for board membership, with no disqualifications or conflicts of interest reported [6][10][21]. - The independent director candidates have completed the necessary training and have been approved by the Shanghai Stock Exchange [6][16]. Group 4: Employee Representative Election - The employee representative director has been elected by the employee representative assembly and will join the newly elected board [20][21].